PubMed Health⌕ Search

Biomedical subjects

A Hellmann

Publications and source records attributed to A Hellmann.

102 records · Page 6Linked to original sources
PubMedDate not supplied

2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.

INTRODUCTION: The aim of the study was to evaluate the results of treatment of Waldenström's Macroglobulinemia with 2-chlorodeoxyadenosine. The evaluation was based on our own experience as well as on the data published previously in the literature. MATERIAL AND METHODS: 25 patients with Waldenström's Macroglobulinemia (MW) were treated with 2-chlorodeoxyadenosine (2-CdA) at the dose of 0.14 mg/kg b.w./day for five consecutive days as 2-hour intravenous infusions. Chemotherapy was repeated every 28 to 35 days. RESULTS: In one case (4%) a complete remission and in 15 patients (60%) a partial remission was achieved. In 6 patients (24%) stabilization of the disease was observed while in 3 patients (12%) progression was noted during the treatment. As a result of the therapy, the mean monoclonal protein concentration decreased from 28.7 g/l (range 5.5-62.5 g/l) to 16.7 g/l (range 0-62.9 g/l) and the mean hemoglobin concentration increased from 10.6 g/dl (range 6.9-13.4) to 12.4 g/dl (range 8.2-14.8 g/dl). CONCLUSION: Our own experience, as well as conclusions of other authors, confirm the effectiveness of 2-CdA in MW treatment. Both the results of treatment and intensity of side effects observed in our treatment group were comparable to those described in previous reports.

Adult↗
PubMedDate not supplied

[Treatment of essential thrombocythemia--personal experience].

The present paper summarizes 13-years our center's experience in the treatment of essential thrombocythemia (ET). We analyzed a group of 36 patients treated with busulphan (Bu), 16 with hydroxyurea (HU) and 4 with interferon alpha (INF alpha). The results of therapy were assessed using proposed self-defined criteria of ET remission. The remission of ET was achieved in 75% of the patients treated with Bu and 57% treated with HU followed for at least 2 years. In the INF alpha treated group cytoreduction was achieved only in patients in whom initial dose of INF alpha was 6 mln I.U. per day. HU seems to be the drug of choice in younger patients because of possible mutagenic effect of Bu as well as in those, in whom Bu was administered in high total dose. During the cytoreductive or maintenance therapy with HU the blood morphology should be often controlled because of relatively high frequency (40%) of leukopenia. In each case of ET cytogenetic examination is necessary. Ph-positive ET determine the choice of the treatment.

Adult↗
PubMedDate not supplied

[Relation between the duration of the chronic phase of chronic myeloid leukemia and total dose of busulfan in the first year of the treatment].

The analysis was based on 31 patients with chronic granulocytic leukaemia (CGL) treated during the period 1975-1986 and the correlation between the total dose of busulphan administered during the first year of treatment and the duration of chronic phase of the disease was investigated. We found such correlation and also we found that the duration of the chronic phase was more significantly correlated with one year maintenance dose of busulphan. This suggests that the prognosis in CGL is more connected with the proliferation activity of leukaemic cells than with the extent of disease at the time of diagnosis.

Adult↗
PubMedDate not supplied

[Leukocyte doubling time as a prognostic factor in chronic lymphocytic leukemia].

The authors present clinical analysis of 57 patients with chronic lymphocytic leukaemia, observed during the first three stages of the disease according to Rai classification. The analysis of the presented material has confirmed the clinical and prognostic value of this classification, but at the same time has shown differences of clinical course of the disease in particular patient. There was no sex neither age effect on the clinical course of chronic lymphocytic leukemia. The authors confirmed that leukocyte doubling time is a very useful prognostic factor in chronic lymphocytic leukaemia.

Adult↗
PubMedDate not supplied

Effect of levamisole on granulopoiesis in agar culture.

We studied the effect of levamisole on the proliferation of granulocyte-committed progenitor cells (CFU-c) in the agar system. Media conditioned by pooled human peripheral blood mononuclear cells served as source of colony-stimulating activity (CSA). Levamisole at concentrations ranging from 0.1 to 10.0 micrograms/ml had no detectable stimulatory or inhibitory effect on granulopoiesis in vitro. Levamisole added to culture media neither enhanced nor reduced the release of mononuclear cells of CSA. We conclude that the cases of granulocytopenia, occasionally severe, associated with levamisole therapy are more likely to be due to individual idiosyncrasy or hypersensitivity then to dose-related myelotoxicity.

Agranulocytosis↗